DOV focus shifts away from bicifadine
This article was originally published in Pharmaceutical Approvals Monthly
DOV Pharmaceutical is implementing a new strategic direction "in which the company will focus its internal efforts on its Phase I and II clinical and preclinical research programs for the development and discovery of drugs to treat neuropsychiatric disorders," the firm announces Oct. 10. Those programs include the firm's triple reuptake inhibitors and preclinical GABA modulators. While DOV had previously been focused on the late stage trials of the analgesic bicifadine, it appears the company now looks at bicifadine as a prime partnering opportunity. DOV is stopping patient dosing in a Phase III back pain trial "in order to best allocate resources"...
You may also be interested in...
US President Joe Biden has invoked the Defense Production Act to ramp up COVID-19 tests and personal protective equipment. See what AdvaMed’s CEO Scott Whitaker wrote in a letter to Biden where he asked that the device industry be included in the administration’s decision-making process.
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
California proposes limiting short-form Prop 65 warnings to products with 5 inches or less of labeling space, while prohibiting their use in online and catalog warnings. The number of products with the warnings, used even on vacuum cleaners, luggage and guitars, has made tracking them impossible.